Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis by Naomi Tsurikisawa et al.
RESEARCH ARTICLE Open Access
Th17 cells reflect colon submucosal
pathologic changes in active eosinophilic
granulomatosis with polyangiitis
Naomi Tsurikisawa1*, Chiyako Oshikata1, Takahiro Tsuburai1, Satoshi Sugano2, Yoko Nakamura2, Takuya Shimoda2,
Shunpei Tamama2, Ken Adachi2, Ayako Horita3, Ikuo Saito3 and Hiroshi Saito4
Abstract
Background: Chronic eosinophilic pneumonia (CEP) or eosinophilic gastroenteritis (EG), or both, with asthma
precede the onset of eosinophilic granulomatosis with polyangiitis (EGPA) in half of all EGPA patients. It is not
known what determines whether patients with CEP or with EG following asthma will develop EGPA.
Methods: We studied 17 EGPA patients and 12 patients with CEP but without EGPA. We assayed serum ICAM-1,
VCAM-1, and VEGF, and the percentage of peripheral blood CD4+ T cells producing IL-17 (Th17 cells), at both onset
and remission. We also examined the numbers of submucosal eosinophils and the basement membrane-to-crypt
and crypt-to-crypt distance to evaluate edema in the colon submucosa at onset and remission in EGPA and at
onset in CEP.
Results: Nine of 12 (75.0 %) CEP patients had symptoms or endoscopic findings. Colonic submucosal eosinophil
counts and edema in EGPA at onset were greater than at remission or in CEP at onset. Th17 cells (%) and serum
ICAM-1 levels at onset were greater in EGPA than in CEP. In EGPA, peripheral blood Th17 cells (%) were significantly
correlated with serum ICAM-1 level, colonic submucosal eosinophil count, and degree of edematous change;
inversely correlated with serum VEGF level; but not correlated with VCAM-1 level.
Conclusions: Eosinophilia and colonic submucosal edematous change were greater in EGPA than in CEP. The
mechanism of vasculitis in EGPA appears related to increases in serum Th17 cell numbers and ICAM-1 levels and
decreases in VEGF levels.
Keywords: Churg-Strauss syndrome, Eosinophilic granulomatosis with polyangiitis, Intercellular adhesion molecule-1,
Vascular cell adhesion molecule-1, Vascular endothelial growth factor
Background
Eosinophilic granulomatosis with polyangiitis (EGPA;
formerly known as Churg-Strauss syndrome) is a rare
disease characterized by allergic granulomatosis and
necrotizing vasculitis developing after the appearance of
peripheral and tissue eosinophilia [1]. Asthma is present
in 96 to 100 % of EGPA patients and is the cardinal fea-
ture of EGPA. Asthma may precede systemic vasculitis
by approximately 8 years and in some cases by more
than 30 years [1–3]. Eosinophilic infiltrations, such as
those found in chronic eosinophilic pneumonia (CEP) or
eosinophilic gastroenteritis (EG), or both, precede sys-
temic vasculitis in half of all patients with EGPA [3, 4].
Some patients with asthma complicated by CEP are
likely to develop EGPA if the CEP is left untreated [5].
However, some patients in whom asthma is complicated
by CEP do not develop EGPA. In our retrospective
cohort study, we found that the clinical manifestations
of asthma occurring in the pre-vasculitic phase of the
disease were severe, or the percentage of eosinophils in
the peripheral blood of pre-EGPA asthmatics at the first
hospital visit was high, but bronchial hyperresponsiveness
to acetylcholine in these pre-vasculitic patients was slight
[6]. We subsequently confirmed that maintenance of
regulatory T cell (Treg cell) numbers in asthma patients
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with CEP may inhibit EGPA development via the action of
cytokines, such as IL-10 and IL-2, produced by CD4+CD25
+ and CD4+CD25− T cells, respectively [7]. However, there
is no clear mechanism that explains why some CEP
patients with asthma develop EGPA and some do not.
Th17 cells play important roles in the immune re-
sponse, depending on their stage of differentiation, be it
induction, amplification, or stabilization. In mice,
transforming growth factor beta (TGF-β) induces the
development of inducible Treg (iTreg) cells by inducing
the expression of the transcription factor forkhead box
P3 (Foxp3) and the production of interleukin (IL)-17A by
CD4+ T cells. IL-6, IL-1β, tumor necrosis factor alpha,
and IL-21, together with TGF-β, promote Th17 differen-
tiation or polarization [8]. Some reports have suggested
that Th17 cells are associated with vasculitis, as occurs in
giant cell arteritis [9], Henoch-Schönlein purpura [10],
antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis [11], granulomatosis polyangiitis or Wegener’s
granulomatosis [12], and EGPA [13, 14].
Intercellular adhesion molecule-1 (ICAM-1) and vas-
cular cell adhesion molecule (VCAM)-1 are expressed
predominantly on the surfaces of endothelial cells and
play an essential role in local leukocyte recruitment to
the vessel wall, adhesion of leukocytes to the endothe-
lium, migration, and extravasation [15, 16]. An enhanced
level of soluble VCAM-1 (sVCAM-1) is a marker of
endothelial cell activation in ANCA-associated vasculit-
ides [15]. Surface expression of ICAM-1, CD11b, and
CD69 on eosinophils in the peripheral blood is increased
in EGPA patients [17]. Vascular endothelial growth factor
(VEGF) is secreted by endothelial cells and pericytes in
response to hypoxia. It induces angiogenesis and micro-
vascular hyperpermeability [18]. Serum VEGF levels are
associated with disease activity, for example in ANCA-
associated vasculitis [19] and systemic vasculitis [20].
Gastrointestinal tract involvement occurs in 17 to
92 % of patients with EGPA [1, 2, 21]. Characteristic
symptoms in EGPA patients are abdominal pain, nausea
or vomiting, diarrhea, hematochezia or melena, and
hematemesis. Gastroduodenal ulceration has been de-
tected endoscopically in 17 (27 %) of 62 patients with
systemic vasculitis (SV) and colorectal ulceration in 6
(10 %), but in one study histologic signs of necrotizing
vasculitis or granuloma could not be found in a number
of small specimen [22]. Patients with EGPA who have
severe gastrointestinal tract involvement, such as surgi-
cal abdomen, can develop peritonitis, bowel perforation,
gastrointestinal ischemia or infarction, and intestinal oc-
clusion, which carry a poor prognosis; mesenteric vascu-
litis may occur, leading to gastrointestinal ulceration,
ischemia, and perforation [23]. Five-year survival rates in
surgical patients with SV (EGPA patients were 11 of 62
patients [22], 82 of 342 patients [24]) have ranged from
41 to 56 % [22, 24]. Colonoscopic findings include mu-
cosal erythema [23] and ulceration [25]. However, in
EGPA specially, the incidence of another minor endo-
scopic signs such as red flare, and edematous change is
not known. Moreover, to our knowledge, there have
been no published investigations of the pathology of
necrotizing vasculitis with infiltration other than eosino-
phils or granuloma. There were various eosinophilic
gastrointestinal diseases shown by drugs or parasitic in-
fection, inflammatory bowel disease, reflux esophagitis,
coeliac disease, microscopic and infectious colitis, SV
(including EGPA), and polyarteritis nodosa [6, 26, 27]. It
is not known whether the intestinal endoscopic findings
characteristics of EG in the asthmatic phase precede SV
in patients with EGPA. Moreover, the pathological differ-
ences in the colon submucosa between patients with
EGPA and those with CEP or other types of EG have
not yet been investigated.
Here, we examined the pathological differences related
to numbers of eosinophils and amount of edema in the
colon submucosa between patients with EGPA and those
with CEP. We also analyzed the relationship between
pathological features and adhesion molecule or growth
factor expression and the Th17 response.
Results
Clinical findings and treatment
There was no significant difference between patients
with EGPA and those with CEP in terms of sex, atopic
or non-atopic, presence or absence of allergic rhinitis or
atopic dermatitis, age at time of onset of asthma, severity
of asthma, and daily inhaled corticosteroid dose for
treatment of asthma (Table 1). In five of 12 patients with
CEP, eosinophilic pneumonitis improved without the pa-
tient taking systemic corticosteroids (i.e. prednisolone).
However, all patients with EGPA received systemic corti-
costeroids (P < 0.01). The initial dose of prednisolone
and the proportion of patients who used immuno-
suppressants or intravenous immunoglobulin (IVIG) were
significantly higher in patients with EGPA than those in
patients with CEP (Table 1; all P < 0.01). Our analysis of
organ involvement revealed no significant differences be-
tween the two groups in terms of the rates of respiratory
system involvement (asthma, paranasal sinusitis, and pul-
monary infiltration) and the rates of involvement of the
liver, gall bladder, and pancreas. EGPA patients had signifi-
cantly higher rates of multiple polyneuropathy and myo-
cardial, renal, skin, muscle, joint, and CNS involvement
than CEP patients (P < 0.01 or P < 0.05).
Gastrointestinal tract characteristics in EGPA and CEP
patients
The incidence of clinical symptoms related to both the
upper and lower abdomen did not differ between the
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two groups (Table 1). There were various findings in the
colonic mucosa (Fig. 1) as well as the gastro-duodenum
mucosa (data not shown) in EGPA patients (ulceration,
erosion, or dark red signs). In contrast, there were only
slight changes in the colonic mucosa, such as red flare,
in patients with CEP (and Fig. 1). However, the overall
incidence of positive colonic mucosal findings on endos-
copy did not differ between the two groups. In contrast,
Table 1 Characteristics and therapies of patients with eosinophilic granulomatosis with polyangiitis (EGPA) or chronic eosinophilic
pneumonia (CEP)
EGPA patients (n = 17) CEP patients (n = 12) P
Age (y), mean ± 1 SD 41.8 ± 15.9 44.2 ± 17.0 NSa
Sex (M/F) 7/10 6/6 NSb
Type: atopy/nonatopy 8/9 4/8 NSb
Allergic rhinitis (yes/no) 9/7 7/5 NSb
Atopic dermatitis (yes/no) 4/13 2/10 NSb
Age at onset asthma (y), mean ± SD 34.5 ± 14.3 36.3 ± 14.4 NSa
Astham severity Step 1/2/3/4 1/0/5/11 2/0/3/8 NSb
Daily dose of ICS (mg; converted to CFC-BDP equivalents) 1482.4 ± 656.0 1173.3 ± 812.3 NSa
Organ involvement at onset of EGPA or CEP patients (%)
Asthma 100 100 NSb
Paranasal sinusitis 94.1 83.3 NSb
Multiple polyneuropathy 100 0 <0.01b
Pulmonary infiltrates 88.2 100 NSb
Myocardinal involvement 76.5 0 <0.01b
Liver, gall bladder, pancreas 17.6 0 NSb
Renal involvementc 41.2 0 < 0.05b
Proteinuria 41.2 0 < 0.05b
Nephritis or nephrosis 11.8 0 NSb
Skin involvement 88.2 25 < 0.01b
Arthritis 52.9 0 < 0.01b
Myalgia 29.4 0 < 0.05b
Central nervous system involvement 29.4 0 < 0.05b
Gastrointestinal tract
Clinical symptoms on the upper abdominal region (yes/no) 10/7 3/9 NSb
Clinical symptoms on the lower abdominal region (yes/no) 12/5 8/4 NSb
Positive signs on mucous membrane of the upper digestive
organs by stomach endscope (yes/no)
10/7 2/10 < 0.05b
Positive signs on mucous membrane of the large intestine by
colon endscope (yes/no)
8/9 5/7 NSb
Treatment for EGPA or CEP
Systemic corticosteroids (yes/no) 17/0 5/7 < 0.01b
Prednisolone per day for initial dose (mg), mean ± 1 SD 45.5 ± 10.7 20.2 ± 5.5 < 0.01a
Patients taking an immunosuppressant (%) 76.5 0 < 0.01b
CYC/AZA/CSA 6/3/4 0/0/0
IVIG (yes/no) 9/8 0/12 < 0.01b
AZA azathioprine, CFC-BDP chlorofluorocarbon-propelled beclomethasone dipropionate, CSA ciclosporin, CYC cyclophosphamide, ICS inhaled corticosteroid, IVIG
intravenous immunoglobulin, NS not significant
All values are expressed as means ± 1 SD
Values of P < 0.05 were considered statistically significant
aTwo-way ANOVA employing a repeated-measures test to explore the significance of differences between any two groups
bChi-squared testing revealed no significant differences in frequency between the two groups
cRenal involvement including protein uria or eosinophils in urin or glomerular nephritis or nephrosis or renal dysfunction
Asthma severity was according to GINA guide lines
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positive gastroscopic findings were more common in
EGPA patients than those in CEP patients (P < 0.05,
Table 1).
Counts and percentages of white blood cells (WBCs),
eosinophils, and Th17 cells, and serum ICAM-1, VCAM-1,
and VEGF levels
The numbers of WBCs and eosinophils in the peripheral
blood at disease onset were significantly higher in EGPA
patients than in CEP patients (P < 0.05 and P < 0.01,
respectively; Table 2). Serum IgE radioimmunosorbent
assay values did not differ between the two groups.
None of the CEP patients was positive for MPO- or
PR3-ANCA. The serum ICAM-1 level at onset was
greater in EGPA patients than in CEP patients (P < 0.05),
but this was not the case for the serum VCAM-1 and
VEGF levels. In EGPA patients, serum ICAM-1, VCAM-1,
and VEGF levels were significantly higher at onset than at
remission, but those in CEP patients did not change
between onset and improvement. The percentage of
CD4+ T cells producing IL-17 (so-called Th17 cells) at
disease onset was significantly higher in patients with
EGPA than in those with CEP (P < 0.01). The percent-
age of Th17 cells in EGPA patients was significantly
lower at remission than at disease onset (P < 0.01), but
there was no change in this percentage in CEP patients
between onset and improvement (Table 2).
Pathological findings in the colon
We could not find any necrotizing vasculitis or granu-
loma in small size samples of submucosa from patients
with either EGPA or CEP. At disease onset there were
significantly more eosinophils in the colonic submucosa
of EGPA patients than of CEP patients (P < 0.05) (Table 2,
Fig. 2). Submucosal eosinophil counts in EGPA were
significantly lower at remission than at onset (P < 0.05).
The localization of submucosal edema varied within each
patient (Fig. 3). The basement membrane-to-crypt interval
and crypt-to-crypt distance reflected the degree of edema
in the colonic submucosa. The basement membrane-to-
crypt and crypt-to-crypt distance at disease onset were
significantly greater in EGPA patients than in CEP pa-
tients (P < 0.01) (Fig. 2). In CEP patients, there were few, if
any, edematous changes in the submucosa. The basement
membrane-to-crypt and crypt-to-crypt distance in EGPA
patients were significantly shorter at remission than at
onset (P < 0.01) (Table 2).
Correlation between eosinophil counts in peripheral
blood and colonic submucosa in patients with EGPA or
CEP
The number of peripheral blood eosinophils in EGPA
patients at both onset and remission was significantly
correlated with the eosinophil count in the submucosa
(P = 0.014, r = 0.42) (Fig. 4a), but this was not the case in
Fig. 1 Endoscopic findings in the large intestine in patients with eosinophilic granulomatosis with polyangiitis (EGPA) (a–c) or chronic
eosinophilic pneumonia (CEP) (d–f). Arrows show ulcer (A), erosion (B), dark red sign (C), and various red flares (D, E, F). The number in bright
green indicated a region biopsied. EGPA patients had subjective symptoms related to the endoscopic findings in the lower digestive organs
(e.g. abdominal pain, diarrhea, and blood in the stool), but there were no subjective symptoms in patients with CEP
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CEP patients at onset (P = 0.42, r = 0.26) (data not
shown).
Correlation between eosinophil count in colonic
submucosa and basement membrane-to-crypt interval in
patients with EGPA or CEP
The number of eosinophils in the colonic submucosa of
EGPA patients at both onset and remission was signifi-
cantly correlated with the basement membrane-to-crypt
distance (P < 0.01, r = 0.61) (Fig. 4b), but this was not the
case in CEP patients at onset (P = 0.37, r = –0.29) (data
not shown). Similarly, the number of eosinophils in the
colonic submucosa of EGPA patients was significantly cor-
related with the crypt-to-crypt distance (P < 0.01, r = 0.53),
but this was not the case in CEP patients at disease (data
not shown). The number of eosinophils in the peripheral
blood of EGPA patients at onset and remission was
significantly correlated with the crypt-to-crypt distance
(P < 0.01, r = 0.52), but again this was not the case in CEP
patients at disease onset (data not shown).
Correlations between percentage of Th17 cells in
peripheral blood and eosinophil count in submucosa,
crypt-to-crypt interval, and basement membrane-to-crypt
interval in patients with EGPA
The percentage of Th17 cells in the peripheral blood of
EGPA patients at onset and remission was significantly
correlated with the submucosal eosinophil count (P < 0.01,
Table 2 Comparison of peripheral blood biomarkers or pathological findings in the large intestinal mucosa between patients with




EGPA patients with at




patients with at onset and
after an improvement




WBC (/mL) in blood,
mean ± 1 SD
15,150 ± 9,062b,a 8,655 ± 2,542 < 0.01a 9,906 ± 4,637 6,928 ± 2,086 < 0.01b
Blood eosinophils (/mL),
mean ± 1 SD
7,356 ± 6,293b,** 142.9 ± 132.7 < 0.01a 3,390 ± 3,575 585.0 ± 443.0 < 0.01a
log IgE RIST in serum 2.910 ± 0.495 0.754 ± 0.259 < 0.01a 2.647 ± 0.505 0.921 ± 0.445 < 0.01a
MPO-ANCA (%) 41.2c,* 0 < 0.05c,* 0 0 NSc
PR3-ANCA (%) 0 0 NSc 0 0 NSc
ICAM-1 level in serum
(ng/mL)
531.5 ± 136.4b,* 392.2 ± 128.3 < 0.01a 372.0 ± 259.6 343.4 ± 37.3 NSa
VCAM-1 level in serum
(ng/mL)
2633.6 ± 4102.7 756.5 ± 563.9 < 0.05a 651.6 ± 132.0 680.2 ± 415.1 NSa
VEGF level in serum
(pg/mL)
231.9 ± 169.4 388.7 ± 265.3 < 0.05a 192.1 ± 99.1 104.8 ± 111.0 NSa
Percentage of CD4+ T cells
producing IL-17 (%)
8.9 ± 5.2b,** 0.7 ± 1.8 < 0.01 2.2 ± 2.7 1.0 ± 1.8 NSa
Pathological findings in colon
Necrotizing vasculitis
(yes/no)
0/17 0/17 NSc 0/12 N.D NSc
Granuloma (yes/no) 0/17 0/17 NSc 0/12 N.D NSc
The number of eosinophils in
submucosa (/mm2)
113.0 ± 46.6b,* 29.5 ± 18.8 < 0.01a 81.9 ± 49.3 N.D
Interval between basement
membrane and crypt (/mm)
7.7 ± 1.3b,** 5.8 ± 1.2 < 0.01a 5.4 ± 1.9 N.D
Interval between crypt and
crypt (/mm)
5.5 ± 1.0b,** 3.7 ± 1.7 < 0.01a 2.8 ± 1.0 N.D
ANCA antineutrophil cytoplasmic antibodies, ICAM-1 intercellular adhesion molecule-1, MPOmyeloperoxidase, NS not significant, PR3 proteinase 3, RIST radioimmunosorbent,
VCAM-1 vascular cell adhesion molecule-1, VEGF vascular endothelial growth factor,WBCs white blood cells
All values are expressed as means ± SD
aStatistical comparisons performed with the Wilcoxon matched-pairs T-test
bTwo-way ANOVA with repeated measures between groups
cChi-squared testing revealed no significant differences between groups
Values of P < 0.05 were considered statistically significant
*EGPA at onset vs. CEP at onset, P < 0.05
**EGPA at onset vs. CEP at onset, P < 0.01
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r = 0.70) (Fig. 5a), with the crypt-to-crypt distance (P < 0.01,
r = 0.53) (Fig. 5b), and with the basement membrane-to-
crypt distance (P < 0.01, r = 0.55) (Fig. 5c).
Correlations between percentage of Th17 cells in
peripheral blood and serum ICAM-1, VCAM-1, and VEGF
levels in patients with EGPA
The percentage of Th17 cells in the peripheral blood
of EGPA patients at onset and remission was signifi-
cantly positively correlated with the serum ICAM-1
level (P < 0.05, r = 0.37) (Fig. 5d) and inversely corre-
lated with the serum VEGF level (P < 0.05, r = – 0.40)
(Fig. 5f ), but it was not correlated with the serum
VCAM-1 level (NS, r = 0.18) (Fig. 5e). The number of
submucosal eosinophils was significantly correlated
with the serum ICAM-1 level (P < 0.01, r = 0.44), but
not with the serum VCAM-1 or VEGF level (data not
shown). The number of eosinophils in the peripheral
blood was significantly correlated with the serum ICAM-1
level (P < 0.05, r = 0.39) and VCAM-1 level (P < 0.01,
r = 0.67), but not with the serum VEGF level (data
not shown). The basement membrane-to-crypt dis-
tance was significantly correlated with the serum
ICAM-1 level (P < 0.05, r = 0.44) but not with the
serum VCAM-1 or VEGF level (data not shown).
Discussion
The 5-year survival rate in EGPA is 62 to 97 % [21, 24,
28–30]. The prognosis of EGPA patients and the extent of
mortality from the disease are associated with disease se-
verity, as assessed by using the Five-Factor Scores devel-
oped in 1996 [24] and 2009 [29]. In addition, myocardial
involvement [2] and the presence of gastrointestinal dis-
ease [2, 31] are independent negative prognostic factors.
However, the gastrointestinal pathology of EGPA has not
yet been fully characterized. Moreover, to our knowledge,
differences in EG have not been investigated between
patients with EGPA at disease onset and patients with
asthma preceding the development of SV in the form of
EGPA. Among the various eosinophilic gastrointestinal
diseases [27, 32], there is less submucosal edema in
ulcerative colitis, Crohn’s disease, and collagenous
colitis [27, 33] than we saw here in our EGPA patients.
Until now there has been a lack of detailed informa-
tion on pathological findings in the colonic submucosa.
In our EGPA patients, we expected to find eosinophilia
but were surprised to find no necrotizing vasculitis or
granuloma. The presence of edematous change was also
previously unreported. The eosinophil count in the sub-
mucosa was significantly correlated with the eosinophil
count in the blood and with the basement membrane-
to-crypt interval in patients with EGPA (Fig. 4), but not
Fig. 2 Pathological findings in the large intestine in patients with eosinophilic granulomatosis with polyangiitis (EGPA) (a–c) or chronic eosinophilic
pneumonia (CEP) (d–f). Evidence of bleeding was present in the submucosa (a). The number of eosinophils in the submucosa was higher in patients
with EGPA (a–c) than in those with CEP (d–f). Edematous changes (expressed as the width of the basement membrane-to-crypt distance or the
crypt-to-crypt distance) were more severe in patients with EGPA than in those with CEP
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Fig. 3 Assessment of number of eosinophils and edema in colonic submucosa in a pathology specimen from a patient with eosinophilic
granulomatosis with polyangiitis. Blue arrows indicate eosinophils. Red arrows show crypt-to-crypt distance. Yellow arrows show basement
membrane-to-crypt distance. All values are expressed as means ± SD in Table 2
Fig. 4 Correlations between eosinophils count (per microliter) in the colonic submucosa and eosinophil count in the peripheral blood (a) or the
basement membrane-to-crypt distance (b) in patients with eosinophilic granulomatosis with polyangiitis (EGPA). The basement membrane-to-crypt
distance reflected edema in the colonic submucosa. Closed circles: mucous membrane of colon biopsied at the onset of EGPA. Open circles: mucous
membrane of colon biopsied in remission after treatment with corticosteroids with or without immunosuppressants. Correlation coefficients (r values)
and P values were calculated by using Spearman’s rank correlation test
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in patients with CEP (data not shown). The lack of cor-
relation in the latter might have been caused by the fact
that in these patients the colon was biopsied only once
(at the onset of CEP), whereas in EGPA patients the
colon was biopsied twice (at disease onset and at remis-
sion). All patients with asthma did not suffer eosino-
philic gastrointestinal disorder. And there were an
infiltration of eosinophils extravascular area in patients
with asthma and without any gastrointestinal symptoms.
Moreover there was an infiltration of number of eosino-
phils extra vascular extravascular tissue in patients with
having more than 2052 number of eosinophils in periph-
eral blood [34].
There were some reports related to type 2 cytokine
and EGPA [35, 36]. However there was little biomarkers
distinguishing between EGPA and another hypereosino-
philic syndrome [37].
We showed here that Th17 cell production decreased
at remission in patients with EGPA. Previously, we
showed that the count of iTreg cells producing IL-10 was
reduced in EGPA patients at disease onset and upon re-
lapse, but increased when the disease was inactive [7].
Here, we investigated FOXP3+/CD4+ T cells as natural
Treg cells in patients with EGPA or CEP. We confirmed
that the percentage of Th17 cells was inversely correlated
with the number of FOXP3+/CD4+ T cells (P < 0.01,
r = -0.57) (data not shown). The number of FOXP3+/CD4+
T cells was significantly correlated with the number of
eosinophils in the colonic submucosa (P < 0.01, r = 0.59)
(data not shown), but unlike the Th17 cell count it was not
correlated with the interval between basement membrane
and crypt or between crypt and crypt (data not shown).
This result indicated that the Th17 cell count but not the
Treg cell count reflected the occurrence of pathological
Fig. 5 Correlations between the percentage of CD4+ T cells producing IL-17 in peripheral blood and eosinophil count in the colonic submucosa
(a); the crypt-to-crypt distance (b); the basement membrane-to-crypt distance (c), the ICAM-1 level (d); the VCAM-1 level (e); and the VEGF level
(f) in the sera of patients with eosinophilic granulomatosis with polyangiitis (EGPA). Closed circles: mucous membrane of colon biopsied at onset
of EGPA. Open circles: mucous membrane of colon biopsied in remission after treatment with corticosteroids with or without immunosuppres-
sants. Correlation coefficients (r values) and P values were calculated by using Spearman’s rank correlation test
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changes related to vasculitis. After treatment of EGPA pa-
tients, the serum ICAM-1 and VCAM-1 levels decreased
significantly, whereas the serum VEGF level increased sig-
nificantly (Table 2). The serum ICAM-1 level was signifi-
cantly correlated with the VCAM-1 level (P = 0.011, r=
0.40) (data not shown). We found previously that multiple
polyneuropathy and cardiac dysfunction improved after
IVIG administration [38], and the numbers of Treg cells (as
FOXP3+/CD4+ T cells or CD4+ T cells producing IL-10)
increased for two years [39].
Maternal sera obtained after IVIG treatment, and poly-
clonal IVIG, decrease constitutive and cytokine-induced
ICAM-1 and VCAM-1 expression on vascular endothe-
lial cells ex vivo [40]. The combination of IVIG and
methylprednisolone generally has a greater suppressive
effect on mRNA expression and on the production of
VCAM-1, IL-1β, and VEGF on endothelial cells derived
from human umbilical vein [41]. IVIG-induced inhib-
ition of angiogenesis has an inhibitory effect on VEGF-
mediated blood perfusion in the ischemic limb in a
mouse model [42]. However, the positive clinical effects
of high-dose IVIG on muscle function in patients with
refractory inflammatory active myositis in the form of
polymyositis or dermatomyositis are not accompanied by
any effects on ICAM-1 and VCAM-1 [43]. We considered
that treatment with various combinations of corticoste-
roids, immunosuppressants, and IVIG induced clinical re-
mission, decreased ICAM-1 and VCAM-1 levels, and
increased VEGF levels. The sICAM-1 level was high in
EGPA patients at disease onset, but the sVCAM-1 level
varied widely and was relatively high at the time of onset
of EGPA. An increase in Th17 cell numbers likely reflects
active vasculitis [14], and an increase in the number of
eosinophils or WBCs might induce upregulation of the ex-
pression of ICAM-1 or VCAM-1 on vascular endothelial
cells; inflammatory cells such as eosinophils and lympho-
cytes, including Th17 cells, then migrate extravascularly
into the colonic submucosa. An increase in serum VEGF
level might have contributed to neovascularization.
We showed the correlation with Th17 cells in per-
ipheral blood and ICAM-1 or VEGF in serum. We
speculated the decrease of the number of Th17 cells
after the treatment of steroid and immunosuppres-
sant might affect the decrease of ICAM-1 and the in-
crease of VEGF. These results were reflected to an
inhibition of migration inflammatory cells and to
promote neovascularization.
Conclusion
In summary, we clarified the pathological and immuno-
logical differences between patients with EGPA and
those with CEP. We expect that this clarification will
help us to diagnose EGPA in the early stages and to start




Between April 2008 and October 2012, we recruited 17
patients with EGPA and 12 patients with CEP but with-
out EGPA. All patients with EGPA and CEP were re-
cruited at the Clinical Research Center for Allergy and
Rheumatology, National Hospital Organization, Sagami-
hara, Kanagawa, Japan. EGPA was defined according to
the classification criteria of the American College of
Rheumatology [44]. Patients with CEP were diagnosed
with asthma by using the criteria of the Global Initiative
for Asthma; the severity of asthma was also rated with
the aid of these guidelines [45]. CEP was defined as the
fulfillment of at least two of three criteria, namely respira-
tory symptoms of more than 2 weeks’ duration; alveolar
or blood eosinophilia (alveolar eosinophilia >25 % on
bronchoalveolar lavage fluid differential cell count; blood
eosinophilia >1000/mm3); and pulmonary infiltrates with
a usually peripheral predominance on chest imaging [46].
Patients with CEP who had allergic bronchopulmonary
mycosis were excluded from the study.
Multiple mononeuritis—a measure of motor nerve
dysfunction—was evaluated by using manual muscle
testing; responses were scored from zero to five on the
Medical Research Council scale. Sensory nerve dysfunc-
tion was evaluated by clinical examination. Lung in-
volvement in EGPA patients was considered present
when any of consolidation, ground grass opacity, nod-
ules within such opacity, interlobular septal thickening,
bronchial wall thickening, lymph node enlargement,
pleural effusion evident upon high-resolution computer
tomography, or eosinophil infiltration detected by lung
biopsy was present. The heart was considered to be in-
volved when any of chest pain, chest discomfort, back pain,
palpitations, abnormal signs on cardiac echocardiography,
Holter electrocardiographic abnormalities, elevated B-
type natriuretic peptide levels, or [123I]-metaiodoben-
zylguanidine myocardial imaging abnormalities of the
myocardium was evident [47]. Gastrointestinal involve-
ment was indicated by the presence of symptoms of
epigastralgia, abdominal pain, diarrhea, or constipation,
or of positive endoscopic signs, combined with con-
firmation of eosinophil infiltration by biopsy. Skin in-
volvement was defined as the presence of purpura,
erythema, livedo, or ulceration, or the presence of acro-
cyanosis when a nodule, accompanied by eosinophilic
infiltration, was additionally detected by biopsy. Central
nervous system involvement was defined as the pres-
ence of headache, visual disorder, abnormal visual sen-
sation, cerebral infarction, bleeding, or cranial nerve
dysfunction. Renal involvement was defined by any of
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the presence of eosinophils in the urine, glomerular
nephritis, nephrosis, renal dysfunction (i.e., creatinine
level >20 % above baseline), or proteinuria (>0.5 g/day).
All patients with EGPA were treated with conventional
therapy (corticosteroids, immunosuppressants, or both; the
initial dose of corticosteroid was approximately 1 mg/kg
prednisolone daily for at least 1 month) [48]. Remission
was defined as the absence of any clinical signs or symp-
toms of active vasculitis for at least 6 months after these
treatments. Patients with CEP who had not entered spon-
taneous remission received treatment with systemic corti-
costeroids in addition to inhaled corticosteroids.
At disease onset and at remission in patients with
EGPA, and at disease onset and improvement in patients
with CEP, we examined the whole blood cell count; eo-
sinophil count in whole blood; serum IgE concentration;
serum MPO- or PR3-ANCA level and ICAM-1, VCAM-
1, and VEGF levels; and the percentage of CD4+ T cells
producing IL-17 in the peripheral blood. Endoscopy of
the large intestine was performed at onset and remission
in patients with EGPA, and at onset in patients with
CEP. The Ethics Committee of our NHO Sagamihara
hospital approved the study, and written informed con-
sent was obtained from each patient.
Endoscopy of the large intestine or the gastro-duodenum
and biopsy of the colon mucosa
Endoscopy of the large intestine was performed after irriga-
tion of the colon with 68 g of magnesium citrate dissolved
in 1800 mL of water; each patient was anesthetized intra-
venously with 3 mg midazolam hydrochloride [49]. A
colonscope (Olympus CF-H290I, Olympus Optical Co.,
Tokyo, Japan) was inserted through the rectum and up into
the sigmoid colon, ascending colon, transverse colon,
descending colon, and ileocecum. Endoscopy of the gastro-
duodenum was performed with using gastro fiberscope
(Olympus GIF-XP260N, Olympus Optical Co., Tokyo,
Japan). At least one point (the gastro-duodenum) or three
points (the large intestine) on the mucous membrane were
biopsied from both visible points and invisible findings.
Measurement of basement membrane-to-crypt interval,
crypt-to-crypt interval, and numbers of eosinophils in
submucosa
Biopsy specimens were fixed in 10 % formaldehyde,
embedded in paraffin, cut at 3 μm, and stained with
hematoxylin and eosin. To our knowledge, there is no
accepted method for measuring the amount of edema in
the colonic submucosa. We therefore chose to assess the
grade of edema in the submucosa in accordance with
the method used in a report by Sanderson et al. [50].
The crypt-to-crypt distance in the submucosa was
measured as the closest distance between two crypts at
10 or more points in randomly selected fields of the
biopsy specimen (Fig. 3). In the same way, the basement
membrane-to-crypt distance was measured as the closest
distance between basement membrane and crypt at 10
or more points. Similarly, the numbers of eosinophils in
the submucosa were counted at five points or more in
randomly selected fields of the biopsy specimen (Fig. 3).
We used image analysis software (Image Pro Plus 6.0,
Media Cybernetics, MD, USA) to evaluate edema and
eosinophilic inflammation in the colonic submucosa. To
determine the number of eosinophils, we counted the
number of cells per slide and then converted that num-
ber to number of eosinophils/mm2. All values are
expressed as means ± SD.
Immunological analysis
Induction of cytokine expression and staining of
intracellular cytokines
Fluorescein isothiocyanate–bearing conjugates of mouse
IgG1 and anti-CD4, and phycoerythrin (PE)-conjugated
anti-human IL-17 were purchased from BioLegend or
R&D Systems (Cosmo Bio Co. Ltd., Tokyo, Japan). To
induce cytokine expression and accumulation, peripheral
blood mononuclear cells (PBMCs, 1 × 106 cells/mL) sus-
pended in RPMI 1640 medium supplemented with 10 %
Fetal Calf Serum (FCS) were stimulated for 4 h at 37 °C
with 10 μg/mL brefeldin A in the presence or absence of
50 ng/mL phorbol myristate acetate (PMA) and 1 μg/
mL ionomycin [51]. Cells that died after this stimulation
were removed. The percentage of dead cells among
PBMCs treated with PMA and ionomycin was calculated
by exclusion-testing by staining with 0.4 % trypan blue
solution. As a control we used whole blood cells diluted
to the same extent in FCS-free RPMI 1640 before the
addition of trypan blue. The percentage of dead cells
was 6.8 ± 6.1 %. Dead cells stained with trypan blue
could not be distinguished in the fluorescence-activated
cell sorting (FACS). However, even if these dead cells
were included, the statistical significance of the percent-
age of positive cells producing cytokines was unaffected.
Surface-stained whole-blood lymphocyte samples were
suspended in 0.5 mL cold 4 % (v/v) paraformaldehyde
(used as a fixative) and incubated at room temperature
for 10 min. Next, the cells were washed twice with
phosphate-buffered saline (PBS) and centrifuged at 200 g
for 7 min. Each pellet thus obtained was suspended in
2 mL serum amyloid P component (SAP) buffer (0.1 %
[w/v] saponin, 0.05 % [w/v] NaN3, in Hanks’s balanced
salt solution). The cell suspension was again centrifuged
at 200 g for 7 min, and the cell pellet was suspended in
0.1 mL SAP buffer. Cell suspensions were diluted with
PBS and aliquoted into tubes containing 106 cells/20 μL.
Phycoerythrin-conjugated anti-IL-17 was added to each
tube. All tubes were vortexed and incubated for 35 min
at room temperature in the dark. The percentage of cells
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generating cytokines was measured with a FACSCalibur
(Nippon Becton Dickinson, Tokyo, Japan) flow cytome-
try system and the data were analyzed with the aid of
CELLQuest software (Nippon Becton Dickinson, Tokyo,
Japan).
Soluble ICAM-1, sVCAM-1, and VEGF levels in serum
Soluble ICAM-1 (sICAM-1), sVCAM-1, and VEGF levels
in the serum were assayed by using Human soluble
ICAM-1, VCAM-1, and VEGF Platinum ELISA kits
(eBioscience, San Diego, CA, USA). For quantification of
sICAM-1 and sVCAM-1, those plates were washed twice
with 400 μg of wash buffer (PBS with 0.05 % Tween 20).
Then 100 μL of Assay Buffer and 100 μL of diluted plasma
(in the case of VCAM-1) or 10 μL of sample (in the case
of ICAM-1) was incubated in each plate well. Fifty mi-
crograms of conjugate mixture (biotin-conjugated anti-
human sICAM-1 or sVCAM-1) was added to the well,
which was then incubated for 1 h (sICAM-1) or 2 h
(sVCAM-1) at room temperature. After each well had
been washed three times, 100 mL of tetramethylbenzi-
dine (TMB) Substrate Solution was added to each well
and the mixture was incubated for 10 min at room
temperature. A stop solution (1 M phosphoric acid) was
then added and the results analyzed by using an ELISA
reader.
For quantification of VEGF, plates were first washed
twice with 400 μg of wash buffer, then 50 μL of Assay
Buffer and 50 μL of sample were incubated in each plate
well for 2 h at room temperature. One hundred micro-
grams of conjugate mixture (biotin-conjugated anti-
human VEGF-A) was added and the well was incubated
for 1 h at room temperature. After the wells had been
washed six times, 100 mL of TMB Substrate Solution
was added to each well and the mixture incubated for
30 min at room temperature. After another six washings
of the wells, VEGF levels were analyzed with an ELISA
reader after addition of the stop solution as above.
Statistical analysis
All values are expressed as means ± SDs unless otherwise
specified. Statistical comparisons among groups were
achieved by using two-way analysis of variance (ANOVA)
employing a repeated-measures algorithm, followed by
post-hoc comparisons using the Newman-Keuls test. Two
mean values were compared by using the Mann-Whitney
U-test. The two mean values obtained by this process
were compared by using the Wilcoxon matched-pairs
T-test. Correlation coefficients were obtained by employ-
ing Spearman’s rank correlation test. P values <0.05 were
considered statistically significant. Statistical analysis was
performed with SPSS for Windows, version 20 (SPSS Inc.,
Chicago, IL).
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